The purpose of this study is to determine whether it is safe to administer Grass-SPIRE to subjects suffering from both grass allergy and asthma
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
54
Intradermal injection
Intradermal injection
Kingston General Hospital
Kingston, Ontario, Canada
Cheema Research Inc
Mississauga, Ontario, Canada
Inflamax Research
Mississauga, Ontario, Canada
Ottawa Allergy Research Corp
Ottawa, Ontario, Canada
Number of subjects with adverse events as a measure of safety and tolerability
Time frame: Throughout subjects participation in the study, approximately 15 weeks
Number of subjects with asthma exacerbations as a measure of safety and tolerability
Time frame: Throughout subjects participation in the study, approximately 15 weeks
Evaluation of change in lung function as a measure of safety and tolerability
Time frame: Throughout subjects participation in the study, approximately 15 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Centre de Recherche Appliquée en Allergie de Québec
Québec, Quebec, Canada